10-Q: iRhythm Narrows Losses, Boosts Revenue on Strong Zio Demand

iRhythm Technologies reported a significant reduction in net loss and strong revenue growth for the third quarter and first nine months of 2025, driven by increased demand for its cardiac monitoring services.

Summary

• Revenue, net, increased by 31% to $192.9 million for the three months ended September 30, 2025, and by 26% to $538.2 million for the nine months ended September 30, 2025, compared to the prior year periods.
• Net loss significantly improved by 89% to $(5.2) million for the three months and by 55% to $(50.1) million for the nine months ended September 30, 2025.
• Adjusted EBITDA turned positive, reaching $21.6 million for the three months and $34.6 million for the nine months ended September 30, 2025, compared to losses in the prior year periods.
• The increase in revenue was primarily driven by higher volume of iRhythm Services, particularly Zio AT, which saw significant growth from new customer accounts and larger healthcare enterprise accounts.
• Offsetting revenue growth were higher contractual allowance reserves, partially due to revisions from billing disruptions caused by the Change Healthcare cybersecurity incident in Q1 2024, and increased payer claims denials.
• Research and development expenses increased by 34% to $21.0 million for the three months and 21% to $63.6 million for the nine months, mainly due to higher employee-related costs, product development consulting, and ongoing FDA remediation.
• Selling, general and administrative expenses rose by 20% to $124.2 million for the three months and 16% to $370.5 million for the nine months, attributed to increased headcount, legal and professional fees, credit loss provisions, claims processing fees, and $7.0 million in intellectual property litigation costs for the nine-month period.
• An impairment charge of $2.5 million was recorded for the nine months ended September 30, 2025, related to internal-use software in development for the Zio Watch, which the company does not intend to commercially launch.
• Net cash provided by operating activities was $54.7 million for the nine months ended September 30, 2025, a significant improvement from cash used in the prior year.
• Net cash used in investing activities increased substantially to $228.3 million for the nine months, primarily due to increased purchases of marketable securities and property and equipment.
• The Development Collaboration Agreement with Verily Life Sciences LLC was mutually terminated in August 2025, with milestones tied to payments totaling $11.0 million achieved to date.
• BioIntelliSense, Inc. achieved the first of two regulatory milestones in June 2025, initiating the process to cancel $10.0 million in Milestone Notes plus accrued interest.

Sentiment

Score: 7

Explanation: The company demonstrated strong revenue growth and significantly reduced its net losses, achieving positive Adjusted EBITDA. While legal and regulatory challenges persist, operational improvements and strategic milestones indicate a positive trajectory. However, increased contractual allowances and substantial cash used in investing activities warrant attention.

Positives

• Revenue, net, increased by 31% to $192.9 million for the three months ended September 30, 2025, and by 26% to $538.2 million for the nine months ended September 30, 2025, demonstrating strong market demand.
• Net loss significantly improved by 89% to $(5.2) million for the three months and by 55% to $(50.1) million for the nine months ended September 30, 2025, indicating progress towards profitability.
• Adjusted EBITDA turned positive, reaching $21.6 million for the three months and $34.6 million for the nine months ended September 30, 2025, reflecting enhanced operational performance and cost management.
• Net cash provided by operating activities was $54.7 million for the nine months ended September 30, 2025, a substantial improvement from cash used in the prior year, strengthening liquidity.
• Increased demand for iRhythm Services, particularly Zio AT, driven by new customer account growth and higher volumes from larger healthcare enterprise accounts.
• BioIntelliSense, Inc. achieved the first of two regulatory milestones in June 2025, leading to the cancellation of $10.0 million in strategic loan investments plus accrued interest, reducing future obligations.

Negatives

• Higher contractual allowance reserves were recognized, partially due to revisions from billing disruptions caused by the Change Healthcare cybersecurity incident in Q1 2024, and increased payer claims denials.
• Selling, general and administrative expenses increased by 20% for the three months and 16% for the nine months, partly due to $7.0 million in intellectual property litigation costs for the nine-month period.
• An impairment charge of $2.5 million was recorded for the nine months ended September 30, 2025, related to internal-use software in development for the Zio Watch, which will not be commercially launched, indicating a failed development effort.
• Net cash used in investing activities increased substantially to $228.3 million for the nine months, primarily due to increased purchases of marketable securities and property and equipment, reducing overall cash balances.
• Cash and cash equivalents decreased from $419.6 million at December 31, 2024, to $255.6 million at September 30, 2025.
• The accumulated deficit increased from $(758.9) million at December 31, 2024, to $(809.0) million at September 30, 2025.

Risks

• Medicare reimbursement is highly regulated and subject to change; failure to comply could prevent reimbursement, lead to penalties, and adversely affect business.
• Reimbursement or other payments for iRhythm Services may be reduced or modified in the U.S. or international markets due to cost containment or changes in coding, coverage, and pricing policies.
• Inability to expand the number of third-party commercial payors with which the company contracts or expand coverage for existing payors could impact commercial success.
• Revenue relies solely on iRhythm Services; failure of current or future service offerings to gain or maintain market acceptance would harm the business.
• The market for remote cardiac monitoring solutions is highly competitive, with competitors potentially developing more effective devices or gaining greater market acceptance.
• Billing for iRhythm Services is complex and highly regulated; failure to comply with legal, regulatory, or contractual requirements could lead to penalties and reputational harm.
• Audits or denials of claims by government agencies or payors could expose the company to recoupment, regulatory scrutiny, and penalties.
• Product enhancements and iterative changes to existing products, or development of new technology, may trigger further unpredictable regulatory reviews.
• Extensive compliance requirements for quality, design, safety, performance, and post-market surveillance of medical devices, as well as vigilance on complaint-handling and adverse event reporting, could lead to enforcement actions.
• A high degree of medical and clinical input may be necessary to evaluate complaints and adverse events, and there may be disagreement over whether services or devices contributed to an event.
• International expansion exposes the company to market, regulatory, political, operational, financial, and economic risks associated with doing business outside the United States.
• Risks associated with acquisitions of companies, products, and technologies, including failure to realize anticipated benefits or greater than anticipated expenditures.
• Use of third-party service providers or company resources located outside the U.S. to support customer care and clinical operations may present challenges and lead to penalties or loss of revenue if not compliant with regulations or contracts.
• Failure to comply with medical device, healthcare, and other governmental regulations could result in substantial penalties.
• Changes in applicable laws or regulations or their interpretation/enforcement policies governing IDTFs and iRhythm Services may require restructuring operations or adapting business strategies.
• Reliance on orders from licensed healthcare providers and strong working relationships with them are subject to high scrutiny by government regulators and enforcement bodies.
• Communications with healthcare stakeholders are subject to high scrutiny for compliance with laws and regulations; increased sales and marketing efforts may expose to additional non-compliance risk.
• Future identification of additional material weaknesses or failure to maintain an effective system of internal controls could result in material misstatements or failure to meet reporting obligations.
• Financial results may fluctuate significantly from quarter-to-quarter due to various factors, including seasonality, and may not fully reflect underlying business performance.
• History of operating losses; may not achieve or sustain profitability in the future.
• May require additional capital to support business growth, and this capital might not be available on acceptable terms, if at all.
• Ability to use net operating losses (NOLs) to offset future taxable income may be subject to limitations, potentially leading to higher tax liability.
• Subject to legal proceedings and government investigations that could adversely affect business, financial condition, and results of operations.
• Subject to complex and evolving U.S. and foreign laws and regulations regarding privacy, data protection, and security, which could result in claims, penalties, and increased costs.
• Cybersecurity risks, including network security breaches and service interruptions, could compromise confidential data or critical systems, leading to harm, costs, liability, and reputational damage.
• Stock price is highly volatile, and investing in the stock involves a high degree of risk.
• Anti-takeover effects of charter documents and Delaware law could make a merger, tender offer, or proxy contest difficult.
• Indebtedness could adversely affect financial health and ability to respond to business changes.
• Servicing debt requires a significant amount of cash, and the company may not have sufficient cash flow to meet obligations.
• Capped call transactions may affect the value of common stock.
• Subject to counterparty risk with respect to capped call transactions.
• Conversion of 2029 Notes will dilute ownership interest of existing stockholders or depress stock price.
• Conditional conversion feature of 2029 Notes, if triggered, may adversely affect financial condition and operating results.
• Accounting method for convertible debt securities could materially affect reported financial results.
• Impacted by domestic and global economic and political conditions, natural disasters, pandemics, and other catastrophic events.
• Environmental, social, and corporate governance (ESG) regulations, policies, and provisions may make the supply chain more complex and adversely affect customer relationships.

Future Outlook

The company anticipates future cash tax benefits due to changes in tax laws for depreciation and research and development expenses, following the One Big Beautiful Bill Act. It also expects continued increases in cost of revenue due to material, labor, and freight costs, partially offset by volume discounts and process improvements. Research and development costs are projected to increase with new product development and enhancements. The company believes its current cash, cash equivalents, and marketable securities balances, together with income from iRhythm Services sales, will be sufficient to meet liquidity requirements for at least the next 12 months.

Management Comments

• "We believe that our current cash, cash equivalents, and marketable securities balances, together with income to be derived from the sales of our iRhythm Services, will be sufficient to meet our liquidity requirements for at least the next 12 months."
• "We continue to expand our other development programs into other clinical-grade wearables to detect and characterize arrhythmias while integrating with clinicians' workflows."
• "We continue to focus on improving annual gross margins in the future, while navigating through the macroeconomic and supply chain headwinds."

Industry Context

The remote cardiac monitoring market is highly competitive and characterized by rapid technological advancements. iRhythm Technologies is navigating this landscape by focusing on its Zio System, which combines a wearable biosensor with cloud-based data analytics. The industry faces increasing scrutiny from third-party payors regarding utilization and cost containment, with government agencies like CMS annually updating reimbursement rates. The company's efforts to integrate AI into its products and services align with broader digital health trends, though this also introduces new regulatory and ethical considerations. The recent termination of the Verily collaboration and the BioIS licensing agreement reflect strategic shifts in product development and partnerships within the evolving healthcare technology sector.

Comparison to Industry Standards

• The remote cardiac monitoring market is highly fragmented, with a few large manufacturers and many smaller regional service providers. iRhythm competes with companies like GE Healthcare, Philips Healthcare, Mortara Instrument, Inc., Spacelabs Healthcare Inc., and Baxter International, Inc. (Welch Allyn, Bardy Diagnostics) in the traditional and patch-based monitoring segments.
• Competitors such as BioTelemetry, Inc. (now part of Royal Philips) and Preventice Solutions, Inc. (now part of Boston Scientific, Inc.) also offer monitoring services and have developed patch-based cardiac monitors.
• Large medical device companies are increasingly acquiring, investing in, or forming alliances with smaller companies to diversify into digital health, a trend iRhythm is participating in through its BioIS licensing agreement.
• The company's focus on AI integration in its Zio AT System aligns with broader industry trends where companies like Apple, Fitbit, and Samsung are adding non-continuous ECG capabilities to consumer wearables, though iRhythm's offerings are clinical-grade.
• The December 2023 FCA settlement by BioTelemetry, Inc. highlights the industry-wide importance of compliance with billing regulations, a risk factor iRhythm also addresses in its filing.

Management Changes

Corporate Governance

Legal Proceedings

• Putative class action lawsuit filed February 6, 2024, alleging violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5, seeking unspecified damages. Motion to dismiss granted in part on June 3, 2025, dismissing all individual defendants except Quentin Blackford. Case is now in discovery.
• Stockholder derivative actions filed in District of Delaware and Northern District of California, making similar allegations to the class action, stayed pending resolution of the securities class action.
• Grand jury subpoenas received March 26, 2021, and September 13, 2021, from U.S. Attorney's Office for Northern District of California, requesting information related to communications with FDA and products/services.
• Subpoena Duces Tecum received April 4, 2023, from Consumer Protection Branch, Civil Division of DOJ, requesting documents regarding products and services. District Court ordered disclosure of certain documents on May 30, 2025, finding waiver of legal privileges. Company appealed to Ninth Circuit, which stayed the order on July 17, 2025. Full briefing expected early next year.
• Patent infringement lawsuit filed February 20, 2024, by Welch Allyn, Inc. (Baxter International, Inc. subsidiary) in District of Delaware, alleging infringement of certain patents by Zio devices. Company denied allegations and asserted patent invalidity. IPR petitions denied institution, and Director review denied in July 2025. Welch Allyn seeks money damages and attorneys fees.
• Patent infringement lawsuit filed December 10, 2024, by Bardy Diagnostics, Inc. (Baxter International, Inc. subsidiary) in District of Delaware, alleging infringement of patents by Zio Monitor patch. Company denied allegations, asserted patent invalidity, and filed counterclaims alleging BardyDx's Carnation Ambulatory Monitor patch infringes five of its patents. Both parties seek money damages and attorneys fees.

Stakeholder Impact

• Shareholders: Potential for dilution from convertible notes, stock price volatility, and impact from legal proceedings and regulatory actions. Improved financial performance could positively impact share value.
• Employees: Stock-based compensation plans, potential for workforce reorganizations, and impact of management changes. Hybrid work arrangements and real estate footprint evaluations may affect work environment.
• Customers (Healthcare Providers/Institutions): Increased demand for iRhythm Services, particularly Zio AT. Impacted by billing complexities, reimbursement changes, and potential supply chain disruptions. Ongoing FDA remediation efforts aim to ensure product quality and regulatory compliance.
• Patients: Continued provision of Zio ambulatory cardiac monitoring services. Potential risks from cybersecurity vulnerabilities in devices and services. Zio Watch development terminated, impacting potential future offerings.
• Payors (Commercial/Government): Higher contractual allowance reserves and increased claims denials. Subject to changes in reimbursement rates and policies (e.g., CMS updates, proposed LCDs). Cybersecurity incidents affecting billing vendors (e.g., Change Healthcare) can cause payment delays.
• Suppliers: Reliance on single-source vendors for critical components, exposing to supply delays and disruptions. Macroeconomic factors and tariffs can increase material costs.
• Creditors (Convertible Note Holders): Indebtedness from 2029 Notes, subject to conversion features and counterparty risk from capped call transactions. Company's ability to service debt depends on future performance.

Next Steps

• Continue to work with the FDA to address issues outlined in the May 25, 2023 warning letter and 2024 483 observations, including follow-up actions and remediation activities.
• Complete contractual conditions with BioIntelliSense, Inc. to cancel $10.0 million in Milestone Notes following the achievement of the first regulatory milestone.
• Continue to evaluate global real estate footprint, which may lead to additional impairment charges related to real property lease agreements.
• Continue to expand product development programs into other clinical-grade wearables to detect and characterize arrhythmias.
• Continue to invest in research and development efforts to further differentiate biosensor, data analytics, information system, and digital platform.
• Continue to assess potential pathways for expanding indications and use cases for iRhythm Services, and developing new products and services for unmet needs in remote cardiac monitoring and adjacent markets (e.g., sleep apnea screening).
• Full briefing on the merits of the DOJ appeal is underway and is not expected to conclude until early next year.
• Government's opposition brief for the DOJ appeal is due November 5, 2025.

Key Dates

Recommendation

The company shows strong revenue growth and a significant reduction in net losses, moving towards profitability with positive Adjusted EBITDA. This indicates improving operational efficiency and market demand for its core products. However, ongoing and complex legal proceedings, including class action lawsuits, DOJ investigations, and multiple patent infringement cases, introduce substantial uncertainty and potential financial liabilities. Additionally, increased contractual allowance reserves and the termination of the Zio Watch project highlight execution challenges. While the operational improvements are positive, the unresolved legal and regulatory risks warrant a cautious 'hold' stance until there is greater clarity on these significant potential headwinds.

Keywords

iRhythm Technologies, IRTC, Cardiac Monitoring, Zio System, ECG, Arrhythmia Diagnosis, Digital Healthcare, Medical Devices, SEC Filing, 10-Q, Financial Results, Revenue Growth, Net Loss Reduction, Adjusted EBITDA, Healthcare Technology, FDA Clearance, BioIntelliSense, Convertible Notes, Legal Proceedings, Cybersecurity, Reimbursement, Healthcare Regulations, Zio AT, Wearable Biosensor